Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision

A. Yu. Goryainova; R. A. Murashko; S. V. Sharov; A. I. Stukan; D. N. Kugaevsky; E. V. Lymar

Meditsinskiy sovet = Medical Council
Meditsinskiy sovet

ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)

User

eng | рус

Meditsinskiy sovet = Medical Council

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Goryainova AY, Murashko RA, Sharov SV, Stukan AI, Kugaevsky DN, Lymar EV. Analysis of the regional clinical use of CDK4/6 inhibitor ribociclib as a mechanism of integration of a research approach in drug provision. Meditsinskiy sovet = Medical Council. 2023;(11):119-131. (In Russ.) https://doi.org/10.21518/ms2023-201

Views PDF (Rus): 252

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)

Editor-in-Chief

Aydar A. Ishmukhametov

* not an advertisement

По рекомендации Президиума ВАК от 8 декабря 2023 г. № 31/1-разн

"О категорировании перечня рецензируемых научных изданий, в которых должны быть опубликованы основные научные результаты диссертаций на соискание ученой степени кандидата наук, на соискание ученой степени доктора наук" журналу «Медицинский совет» присвоена категория К1

Popular articles

Indexing Databases

* not an advertisement

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

A. Yu. Goryainova
Clinical Oncologic Dispensary No. 1; Kuban State Medical University
Russian Federation

Alla Yu. Goryainova, Medical Oncologist, Head of the Drug Supply Coordination Department; Assistant of the Department of Oncology with the course of Thoracic Surgery